Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Fairtility Expands European Market Penetration with CHLOE EQ ™, as Clinics in Five Countries Embrace Breakthrough AI Technology in IVF

Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced today its expanding geographic footprint across Europe. One year since receiving CE MDR clearance for CHLOE EQ™, Fairtility has established a strong presence in countries, including the United Kingdom, Spain, Turkey, Greece, and Norway, in its mission to transform the IVF landscape.

“Clinics across Europe have embraced CHLOE EQ™, and they are seeing the disruptive capabilities of the platform, both in terms of embryo selection and providing patients the most advanced and transparent IVF experience available,” said Eran Eshed, CEO and Co-founder of Fairtility. “These clinics are charting the path forward as AI progresses to become part of the standard of care across the IVF journey.”

Fairtility has implemented its transparent AI tool in 10 clinics, including:

With 1 in 6 people experiencing infertility in their reproductive years, the IVF market is growing.  Fertility care providers must expand capacity by seeking opportunities to create workflow efficiencies both within and beyond the embryology lab. CHLOE EQ™ represents a breakthrough in the IVF field, enabling clinics to reduce time spent on manual embryo annotation by an average of 33 percent per cycle. This has resulted in a 30-50 percent increase in IVF cycle capacity in clinics.

“Implementing AI technologies entering the IVF space challenges traditional norms and drives innovation forward for the entire industry,” said Suzanne Cawood, Director of Embryology, CRGH UK. “AI tools like CHLOE EQ™ are necessary for improving the efficiency of IVF processes and increasing transparency. They are also the answer to IVF professional shortages and embryologist burnout resulting from the volume of administration associated with a single IVF cycle. Fairtility’s AI makes IVF more efficient and accessible to the growing population of people seeking fertility treatment.”

To thrive in the digital age, clinics must embrace a fully digital IVF journey that is streamlined and transparent for all stakeholders. Fairtility understands this imperative and is supporting clinics in achieving digital transformation for the IVF journey. CHLOE EQ™integrates with leading IVF EMR providers, enabling data to flow freely from lab-to-fertility specialist-to-patient, paving the path for more open communication on treatment plans and progress.

“We selected CHLOE EQ because of its ability to provide quantifiable biological data on embryo development, quality and viability. This transparency and interpretability set it apart from other AI-based decision support tools available,” said Shabana Sayed, Senior Embryologist and IVF Lab Manager at Klinikk Hausken, part of Medicover. “Our embryologists see this system as a companion that helps augment and standardize decision making. It speaks to them in a language they understand –human biology.”

CHLOE EQ™ is the only commercial AI decision support platform able to quantify biomarkers throughout embryo development, automatically analyzing established morphological and morphokinetic features, which are traditionally captured in a time-consuming and subjective manner. Through translation of computational information to biologically relevant interpretation made ready for clinical decision making, CHLOE is the first and only transparent AI system able to automate analysis of the full spectrum of biological events related to embryo development.

“Together with our visionary partner clinics, we are reshaping the fertility landscape, addressing the urgent need for improved outcomes, and providing patients with the transparency and control they desire,” said Eshed.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy